Clinical Trial: Phase II Study of Sintilimab Combined with Ipilimumab N01, Cetuximab, and Dabrafenib in the Treatment of Microsatellite Stable, BRAF V600E-mutant Metastatic Colorectal Cancer (China)

China, Sept. 24 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Phase II Study of Sintilimab Combined with Ipilimumab N01, Cetuximab, and Dabrafenib in the Treatment of Microsatellite Stable, BRAF V600E-mutant Metastatic Colorectal Cancer'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600133230

Registration Time: 2026/09/23

Type: Interventional study

Primary Sponsor: Tianjin Medical University Cancer Institute and Hospital

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=325922

Published by HT Digital Content Services with permission from Health Daily Digest....